About the AuthorSergey V. Nedogoda 1 , Minara S. Shamkhalova 2 , Alla S. Salasyuk 1 , Viktoriya O. Lutova 1 , Irina N. Barykina 1 , Ekaterina A. Popova 1
1 Volgograd State Medical University, Volgograd, Russia
2 Endocrinology Research Centre, Moscow, Russia
For citation:Nedogoda S.V., Shamkhalova M.S., Salasyuk A.S., Lutova V.O., Barykina I.N., Popova E.A. Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation. Clinical review for general practice. 2022; 2: 33–43. DOI: 10.47407/kr2022.3.2.00128
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.